Product
Pelacarsen
Aliases
Pelacarsen (TQJ230) 80 mg s.c., TQJ230
4 clinical trials
4 indications
Indication
HyperlipoproteinemiaIndication
Hyperlipoproteinemia (a)Indication
Aortic StenosisIndication
Liver ImpairmentClinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in GermanyStatus: Active (not recruiting), Estimated PCD: 2025-06-27
Clinical trial
A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.Status: Recruiting, Estimated PCD: 2028-08-24
Clinical trial
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]Status: Recruiting, Estimated PCD: 2029-01-03
Clinical trial
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-10-19